News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Progenics Pharmaceuticals, Inc. (PGNX)' PSMA ADC Data Selected For Poster Highlight Presentation At American Society of Clinical Oncology 2014


5/30/2014 8:27:42 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

TARRYTOWN, N.Y., May 30, 2014 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company that is developing innovative approaches to targeting and treating prostate cancer, announced today that results from its phase 2 trial of PSMA ADC have been chosen to be included in the genitourinary (prostate) cancer poster highlights session at the annual meeting of the American Society of Clinical Oncology being held in Chicago, Illinois on May 30 – June 3. These data update previously presented results from a study of 83 patients with metastatic castrate-resistant prostate cancer who suffered from progressive disease despite treatment with at least one taxane-containing chemotherapy.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES